Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 6/2020

20.02.2020 | Original Article

Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection

verfasst von: Ilya Tsimafeyeu, Rustem Gafanov, Svetlana Protsenko, Anna Semenova, Ani Oganesyan, Nurzhan Nurgaliyev, Sergei Krasny, Anastasia Bondarenko, Sufia Safina, Kristina Zakurdaeva

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepatitis C virus (HCV) interferes with activation of innate and adaptive immune responses. Theoretically, the efficacy and toxicity of immune checkpoint inhibitors in cancer patients infected with HCV may differ. Nevertheless, HCV was an exclusion criterion in most checkpoint inhibitor trials. We evaluated the efficacy and safety of nivolumab in metastatic renal cell carcinoma (mRCC) patients with or without chronic HCV infection.

Methods

In a matched cohort study, data were collected from 174 patients, retrospectively. All patients had clear-cell mRCC, chronic HCV infection (case study group), no evidence of other malignancy or cirrhosis, and had received nivolumab (3 mg/kg every 2 weeks) until disease progression or unacceptable toxicity. Quantitation of HCV RNA in plasma samples was performed before and during treatment with nivolumab with the automated HCV test (Hoffmann-La Roche, Switzerland). The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and rate of grade 3–4 adverse events in study and control cohorts.

Results

A total of 44 matched patients were included. Groups were well balanced. HCV-infected patients had significantly longer OS and PFS. Median OS was 27.5 (95% CI 25.3–29.7) and 21.7 (20.3–23.1) in study and control groups, respectively (P = 0.005). Median PFS was 7.5 (5.7–9.3) and 4.9 (4–5.8) (P = 0.013). Despite no differences in ORR between groups (27% vs. 23%, P = 0.7), patients with HCV had significantly more durable responses (P = 0.01). Nivolumab was well tolerated in all HCV-positive patients. No unexpected toxicity was observed. Assessment of viral load during nivolumab therapy was available in 14 of 22 (64%) patients with HCV. Nivolumab did not significantly impact HCV concentration (mean change 210 IU/ml, P = 0.82) in the absence of antiviral therapy.

Conclusions

The efficacy and safety profiles observed in this study support the administration of nivolumab in mRCC patients infected with HCV and warrant further investigation.
Literatur
1.
Zurück zum Zitat Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH (2016) Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol 34:539–573CrossRef Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH (2016) Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol 34:539–573CrossRef
2.
Zurück zum Zitat Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264CrossRef Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264CrossRef
3.
Zurück zum Zitat Tsimafeyeu I, Zolotareva T, Varlamov S, Zukov R et al (2017) Five-year survival of patients with metastatic renal cell carcinoma in the Russian Federation: results from the RENSUR5 registry. Clin Genitourin Cancer 15(6):e1069–e1072CrossRef Tsimafeyeu I, Zolotareva T, Varlamov S, Zukov R et al (2017) Five-year survival of patients with metastatic renal cell carcinoma in the Russian Federation: results from the RENSUR5 registry. Clin Genitourin Cancer 15(6):e1069–e1072CrossRef
4.
Zurück zum Zitat Wykes MN, Lewin SR (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18(2):91–104CrossRef Wykes MN, Lewin SR (2018) Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 18(2):91–104CrossRef
5.
Zurück zum Zitat Kaplan DE (2015) Immunopathogenesis of hepatitis C virus infection. Gastroenterol Clin 44:735–760CrossRef Kaplan DE (2015) Immunopathogenesis of hepatitis C virus infection. Gastroenterol Clin 44:735–760CrossRef
6.
Zurück zum Zitat Wedemeyer H, He XS, Nascimbeni M, Davis AR et al (2002) Impaired effector function of hepatitis C virus-specific CD8 + T cells in chronic hepatitis C virus infection. J Immunol 169(6):3447–3458CrossRef Wedemeyer H, He XS, Nascimbeni M, Davis AR et al (2002) Impaired effector function of hepatitis C virus-specific CD8 + T cells in chronic hepatitis C virus infection. J Immunol 169(6):3447–3458CrossRef
7.
Zurück zum Zitat Johnson DB, Sullivan RJ, Menzies AM (2017) Immune checkpoint inhibitors in challenging populations. Cancer 123(11):1904–1911CrossRef Johnson DB, Sullivan RJ, Menzies AM (2017) Immune checkpoint inhibitors in challenging populations. Cancer 123(11):1904–1911CrossRef
8.
Zurück zum Zitat World Health Organization (2017) Global hepatitis report 2017. World Health Organization, Geneva World Health Organization (2017) Global hepatitis report 2017. World Health Organization, Geneva
9.
Zurück zum Zitat Hofmeister MG, Rosenthal EM, Barker LK et al (2019) Estimating prevalence of hepatitis C virus infection in the United States, 2013–2016. Hepatology 69(3):1020–1031CrossRef Hofmeister MG, Rosenthal EM, Barker LK et al (2019) Estimating prevalence of hepatitis C virus infection in the United States, 2013–2016. Hepatology 69(3):1020–1031CrossRef
10.
Zurück zum Zitat Ramsey SD, Unger JM, Baker LH et al (2019) Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices. JAMA Oncol 5(4):497–505CrossRef Ramsey SD, Unger JM, Baker LH et al (2019) Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices. JAMA Oncol 5(4):497–505CrossRef
11.
Zurück zum Zitat Tagliamento M, Grossi F, Paolino S et al (2019) Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. Immunotherapy 11(10):873–879CrossRef Tagliamento M, Grossi F, Paolino S et al (2019) Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. Immunotherapy 11(10):873–879CrossRef
12.
Zurück zum Zitat Davar D, Wilson M, Pruckner C et al (2015) PD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIV. Case Rep Oncol Med 2015:737389PubMedPubMedCentral Davar D, Wilson M, Pruckner C et al (2015) PD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIV. Case Rep Oncol Med 2015:737389PubMedPubMedCentral
13.
Zurück zum Zitat Kothapalli A, Khattak MA (2018) Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. Melanoma Res 28(2):155–158CrossRef Kothapalli A, Khattak MA (2018) Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. Melanoma Res 28(2):155–158CrossRef
14.
Zurück zum Zitat Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389(10088):2492–2502CrossRef Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389(10088):2492–2502CrossRef
15.
Zurück zum Zitat Finn RS, Ryoo B-Y, Merle P et al (2020) Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 38(3):193–202CrossRef Finn RS, Ryoo B-Y, Merle P et al (2020) Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 38(3):193–202CrossRef
16.
Zurück zum Zitat Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15(8):486–499CrossRef Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15(8):486–499CrossRef
17.
Zurück zum Zitat Salem ML, El-Badawy A (2015) Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World J Hepatol 7:2449–2458CrossRef Salem ML, El-Badawy A (2015) Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World J Hepatol 7:2449–2458CrossRef
18.
Zurück zum Zitat Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R et al (2013) A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 8:e63818CrossRef Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R et al (2013) A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 8:e63818CrossRef
Metadaten
Titel
Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection
verfasst von
Ilya Tsimafeyeu
Rustem Gafanov
Svetlana Protsenko
Anna Semenova
Ani Oganesyan
Nurzhan Nurgaliyev
Sergei Krasny
Anastasia Bondarenko
Sufia Safina
Kristina Zakurdaeva
Publikationsdatum
20.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 6/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02521-y

Weitere Artikel der Ausgabe 6/2020

Cancer Immunology, Immunotherapy 6/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.